2019
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, Velazquez EJ, Shah SJ. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal Of Cardiac Failure 2019, 26: 270-275. PMID: 31857197, PMCID: PMC7078046, DOI: 10.1016/j.cardfail.2019.12.001.Peer-Reviewed Original ResearchConceptsLA reservoir strainLA myopathyHeart failureNT-proBNPEjection fractionLA reservoirReservoir strainLA strainN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAtrial mechanical dysfunctionEjection Fraction trialLA contractile strainLower LA reservoirJugular venous pressurePoor clinical outcomePhosphodiesterase-5 inhibitionAssociation of LAAtrial myopathyBaseline echocardiogramRELAX trialNeurohormonal activationExercise capacityVenous pressureClinical outcomes
2013
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor C, Felker GM, Goldsmith SR, Bart B, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial F. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2013, 309: 1268-1277. PMID: 23478662, PMCID: PMC3835156, DOI: 10.1001/jama.2013.2024.Peer-Reviewed Original ResearchConceptsPeak oxygen consumptionPhosphodiesterase-5 inhibitionExercise capacityWalk distanceEjection fractionHeart failureClinical statusPlacebo patientsAdverse eventsClinical trialsFilling pressureN-terminal brain-type natriuretic peptideElevated left ventricular filling pressureMedian peak oxygen consumptionPulmonary artery systolic pressureLeft ventricular filling pressureBrain-type natriuretic peptidePhosphodiesterase-5 inhibitor sildenafilEnd pointOxygen consumptionPrimary end pointSecondary end pointsVentricular filling pressureWeek 24 dataWeeks of therapy